Original endomorphin-1 analogues exhibit good analgesic effects

被引:5
|
作者
Wu, Yanjing [1 ]
Zhao, Xinyi [1 ]
Gan, Yongan [1 ]
Zhang, Xuehong [1 ,2 ]
Wei, Hongbin [1 ]
Wang, Lewei [1 ,2 ]
Liang, Xiaolei [1 ,2 ]
Gao, Xuelin [1 ]
Liu, Ying [1 ]
Hu, Junping [1 ,2 ]
Wang, Yiqing [1 ,2 ]
机构
[1] First Hosp Lanzhou Univ, Lanzhou 730000, Peoples R China
[2] Key Lab Reprod Med & Embryo, Lanzhou 730000, Peoples R China
基金
中国国家自然科学基金;
关键词
Endomorphin-1; analogues; Metabolic stability; Analgesic activity; BLOOD-BRAIN-BARRIER; PHARMACOLOGICAL CHARACTERIZATION; PERMEABILITY; ANTINOCICEPTION; STABILITY; MORPHINE; AGONISTS; PEPTIDE; DESIGN; POTENT;
D O I
10.1016/j.bmcl.2017.02.034
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A new class of endomorphin-1 analogues was synthesized by combining successful chemical modifications including N-terminal guanidino modification, Phe(4) was chlorinated, D-Ala-Gly Substituted L-Pro(2). Their bioactivities were measured by radioligand binding assay, metabolic stability and the tail-flick test. In radioligand binding assays, analogue GAGPC (N-alpha-Amidino-Tyr-D-Ala-Gly-Trp-p-Cl-Phe-NH2), shown a mu-opioid receptor affinity about 1.42-fold higher and a 2.51-fold higher delta-opioid receptor affinity than EM-1. In the metabolic stability assays, GAGPC had the longest half-lives which was 284 min and 53-fold higher than that of EM-1. In the tail-flick test in mice, GAGPC chloride modification increases the lipid content of the drug, thus increases the permeability of the blood brain barrier, and has a higher analgesic activity. It might be of importance in potential application as drug candidates as analgesic. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1557 / 1560
页数:4
相关论文
共 50 条
  • [21] Endomorphin-1 induces antinociception without immunomodulatory effects in the rat
    K.A. Carrigan
    C.J. Nelson
    D.T. Lysle
    Psychopharmacology, 2000, 151 : 299 - 305
  • [22] Endomorphin-1 induces antinociception without immunomodulatory effects in the rat
    Carrigan, KA
    Nelson, CJ
    Lysle, DT
    PSYCHOPHARMACOLOGY, 2000, 151 (04) : 299 - 305
  • [23] Analgesic tolerance and cross-tolerance to i.c.v. endomorphin-1, endomorphin-2, and morphine in mice
    Soignier, RD
    Vaccarino, AL
    Fanti, KA
    Wilson, AM
    Zadina, JE
    NEUROSCIENCE LETTERS, 2004, 366 (02) : 211 - 214
  • [24] Antinociceptive effects of intrathecal endomorphin-1 and-2 in rats
    Horvath, G
    Szikszay, M
    Tömböly, C
    Benedek, G
    LIFE SCIENCES, 1999, 65 (24) : 2635 - 2641
  • [25] Antinociceptive effects of intrathecal endomorphin-1 and-2 in rats
    Szikszay, M
    Horvath, G
    Joo, G
    Benedek, G
    BRITISH JOURNAL OF ANAESTHESIA, 1999, 82 : 201 - 202
  • [26] Differential antinociceptive effects induced by intrathecally administered endomorphin-1 and endomorphin-2 in the mouse
    Sakurada, S
    Hayashi, T
    Yuhki, M
    Orito, T
    Zadina, JE
    Kastin, AJ
    Fujimura, T
    Murayama, K
    Sakurada, C
    Sakurada, T
    Narita, M
    Suzuki, T
    Tan-no, K
    Tseng, LF
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 427 (03) : 203 - 210
  • [27] In vivo characterization of intestinal effects of endomorphin-1 and endomorphin-2 in type 1 diabetic mice
    Wang, Chang-lin
    Zhou, Ying
    Guo, Chao
    Zhang, Ying
    Wang, Rui
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, 698 (1-3) : 499 - 504
  • [28] The antinociceptive properties of endomorphin-1 and endomorphin-2 in the mouse
    Tseng, LF
    JAPANESE JOURNAL OF PHARMACOLOGY, 2002, 89 (03): : 216 - 220
  • [29] Diabetes attenuates the inhibitory effects of endomorphin-2, but not endomorphin-1 on gastrointestinal transit in mice
    Wang, Chang-lin
    Diao, Yu-xiang
    Xiang, Qiong
    Ren, Yu-kun
    Gu, Ning
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, 738 : 1 - 7
  • [30] Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain
    Goldberg, IE
    Rossi, GC
    Letchworth, SR
    Mathis, JP
    Ryan-Moro, J
    Leventhal, L
    Su, W
    Emmel, D
    Bolan, EA
    Pasternak, GW
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1998, 286 (02): : 1007 - 1013